San Diego, CA, United States of America

Killian Oukoloff

This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignees: University of California, University of Pennsylvania. Active years: 2023.

USPTO Granted Patents = 1 

% Patents Active = 100.0


Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2023

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Killian Oukoloff: Innovator in Microtubule Stabilization

Introduction

Killian Oukoloff is a notable inventor based in San Diego, CA. He has made significant contributions to the field of pharmaceuticals, particularly in the area of microtubule stabilization. His innovative work has implications for treating various diseases, including cancer and neurodegenerative disorders.

Latest Patents

Killian Oukoloff holds a patent for "Substituted [1,2,4]triazolo[1,5-a]pyrimidines for stabilizing microtubules." This patent describes compounds that can stabilize microtubules, which are essential for various cellular functions. The patent outlines methods for administering these compounds to patients, aiming to provide therapeutic benefits for conditions such as cancer and neurodegenerative diseases.

Career Highlights

Throughout his career, Killian has worked with prestigious institutions, including the University of Pennsylvania and the University of California. His experience in these academic environments has allowed him to collaborate with leading researchers and contribute to groundbreaking studies.

Collaborations

Killian has collaborated with notable colleagues, including Carlo Ballatore and Amos B. Smith III. These partnerships have enriched his research and expanded the impact of his inventions.

Conclusion

Killian Oukoloff is a distinguished inventor whose work in microtubule stabilization holds promise for advancing medical treatments. His contributions to the field are noteworthy and continue to influence research and development in pharmaceuticals.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…